JJK Holdings Ltd. Acquires $7,878,792 Convertible Debenture Of Noveris Health Sciences Inc.; Filing Of Early Warning Reports By JJK Holdings Ltd.

Core Viewpoint - Noveris Health Sciences Inc. announces the acquisition of a convertible debenture worth CAD $7,878,792 by JJK Holdings Ltd., previously held by Pioneer Garage Limited, which could lead to significant dilution of existing shares if converted [1][2][3]. Group 1: Acquisition Details - JJK Holdings Ltd. acquired a convertible debenture from Pioneer Garage Limited, which matures on October 14, 2026, and is convertible at a price based on the greater of the 20-day trailing volume-weighted average trading price or the minimum conversion price set by the Canadian Securities Exchange [1][2]. - The debenture could result in the issuance of approximately 42,588,065 common shares to JJK, representing 97.18% of the company's total issued and outstanding shares, assuming a conversion price of CAD $0.185 per share [3][5]. Group 2: Shareholder Changes - Prior to the acquisition, Pioneer held the debenture, which would have given it approximately 97.18% of the company's shares upon conversion. After the acquisition, Pioneer no longer holds any securities of the company [5]. - JJK did not own any securities of the company before the acquisition and may acquire additional securities in the future depending on market conditions [4][5]. Group 3: Company Overview - Noveris Health Sciences Inc. is a biotechnology company focused on developing innovative medications and therapies for mental health disorders, including nicotine addiction and PTSD [8][9]. - The company's strategy involves advanced technology and a robust infrastructure for drug discovery, aiming to create breakthrough treatments in areas with significant unmet needs [8][9].